Abstract
Comparison of Efficacy of Topical Clobetasol Propionate 0.05% and Topical Tacrolimus 0.1% in the Treatment of Lichen Planus
Ayesha Arshad Chattha1, Saadiya Siddiqui2, Faria Asad3, Shahbaz Aman4
Keywords: Lichen planus, mucocutaneous lesions, tacrolimus, clobetasol, eff
DOI: 10.63475/yjm.v4i2.0185
DOI URL: https://doi.org/10.63475/yjm.v4i2.0185
Publish Date: 22-09-2025
Download PDFPages: 429 - 434
Citation: 0
Author Affiliation:
1 Senior Registrar, Department of Dermatology, Ghurki Trust Teaching Hospital, Lahore, Pakistan
2 Assistant Professor, Department of Dermatology, Ameer-Ud-Din Medical College, Lahore General Hospital, Lahore, Pakistan
3 Professor, Department of Dermatology, Services Institute of Medical Sciences, Services Hospital Lahore, Lahore, Pakistan
4 Professor, Department of Dermatology, Sahara Medical College, Narowal, Pakistan
Abstract
Background: Lichen planus (LP) is a papulosquamous cutaneous disorder that manifests as intensely itchy violaceous flat-topped polygonal papules and plaques. To compare the efficacy of topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in the treatment of LP.
Methods: This prospective Comparative Study was conducted at the Dermatology Department, Services Institute of Medical Sciences (SIMS)/Services Hospital, Lahore, from May 1, 2022, to April 30, 2023. Ethical approval was obtained from the institutional review board at the Department of Dermatology, SIMS/Services Hospital, Lahore. A total of 80 patients were selected after fulfilling the selection criteria. The study participants were placed into two groups, A and B. In group A, the patients were advised to use the topical application of clobetasol propionate (0.05%) ointment twice daily. In group B, tacrolimus ointment (0.1%) was used twice daily. Treatment response was assessed at 3 weeks, and then finally efficacy was evaluated at 6 weeks.
Results: Treatment efficacy was observed in 34 patients (42.5%). Group A (Clobetasol) demonstrated a significantly higher efficacy of 55% compared to 30% in Group B (Tacrolimus; p = 0.024).
Conclusions: The 0.05% clobetasol propionate topical formulation demonstrated superior efficacy in treating LP compared to 0.1% topical tacrolimus. Further validation of these findings through large-scale clinical trials is warranted.